| Current Price | $2.19 | Mkt Cap | $221.8M |
|---|---|---|---|
| Open | $2.21 | P/E Ratio | -1.01 |
| Prev. Close | $2.19 | Div. (Yield) | $0.00 (0.0%) |
| Daily Range | $2.11 - $2.23 | Volume | 2,706,775 |
| 52-Wk Range | $2.11 - $23.96 | Avg. Daily Vol. | 2,347,835 |
| Current Price | $2.19 | Mkt Cap | $221.8M |
|---|---|---|---|
| Open | $2.21 | P/E Ratio | -1.01 |
| Prev. Close | $2.19 | Div. (Yield) | $0.00 (0.0%) |
| Daily Range | $2.11 - $2.23 | Volume | 2,706,775 |
| 52-Wk Range | $2.11 - $23.96 | Avg. Daily Vol. | 2,347,835 |
The best Bull and Bear pitches based on recency and number of recommendations.
It’s got the Boomstick Baby
There are no pitches that meet the Top Bear criteria. Explain
If this upsets you, start recommending pitches below!
Read the most recent pitches from players about FATE.
Recs
Checkmating2021
(< 20)
Submitted: 9/1/2021 5:04:08 PM :
Start Price:
$76.10
NASDAQ:FATE Score:
-92.28
It’s got the Boomstick Baby
Recs
ted368
(< 20)
Submitted: 10/6/2020 1:51:34 PM :
Start Price:
$41.89
NASDAQ:FATE Score:
-121.34
Solid Partner in product and development.
Recs
NoPlaceLikeHome
(< 20)
Submitted: 3/9/2017 10:28:18 AM :
Start Price:
$4.09
NASDAQ:FATE Score:
-128.52
With a phase 3 trial that can support an FDA application for approval of Zilretta, a non-opioid therapy for knee pain in osteoarthritis patients, under their belt, they are on the road to final approval. Long story short, if it gets the FDA green light, 10% market penetration is over $1B in revenue. It is non-opiod which means prescribers and patients do not have to hassle with increased scrutiny writing and filling scripts and I believe that will make market penetration very easy. At under $200 million in market cap and a $1B+ opportunity, I can't pass up the risk/reward. Buy!!
Find the members with the highest scoring picks in FATE.
headyinvestor (< 20) Score: +1,244.40
The Score Leader is the player with the highest score across all their picks in FATE.
|
Top Pick |
Member Name |
Member Rating |
Start Date |
Call |
Time Frame |
Start Price |
Stock Gain |
Index Gain |
Score | Commentary |
|---|---|---|---|---|---|---|---|---|---|---|
| Origin97 | 32.92 | 4/15/2014 |
|
NS | $7.58 | -71.11% | +135.32% | +206.43 | 0 Comment | |
| MMCapitalMgmt | 99.96 | 5/11/2015 |
|
5Y | $7.40 | -70.41% | +103.90% | +174.30 | 0 Comment | |
| Under5 | 56.15 | 8/24/2023 |
|
5Y | $2.59 | -15.28% | -1.66% | -13.62 | 0 Comment | |
| curmie | 34.13 | 3/22/2023 |
|
5Y | $5.42 | -59.59% | +8.19% | -67.79 | 0 Comment | |
| stainsolution | < 20 | 2/17/2016 |
|
5Y | $1.57 | +39.94% | +123.68% | -83.74 | 0 Comment | |
| foggs1 | 60.78 | 3/30/2022 |
|
5Y | $41.20 | -94.68% | -6.29% | -88.40 | 0 Comment | |
| Kuddel55 | < 20 | 12/6/2021 |
|
5Y | $47.18 | -95.36% | -6.09% | -89.27 | 0 Comment | |
| Caprese | < 20 | 10/22/2021 |
|
5Y | $58.23 | -96.24% | -4.91% | -91.33 | 0 Comment | |
| Checkmating2021 | < 20 | 9/2/2021 |
|
5Y | $76.10 | -97.12% | -4.84% | -92.28 | 1 Comment | |
| sorrycharlie1 | 61.67 | 3/1/2022 |
|
5Y | $35.18 | -93.77% | -0.84% | -92.94 | 0 Comment |
See what the Wall Street professionals think, according to their public statements and filings.
